Abstract:
:Appropriate treatment for nonreactive thrombocytosis resulting from a myeloproliferative disorder (MPD) is surrounded by controversy. Although few doubt the association of thrombocytosis with increased risk for life-threatening events such as thrombosis or hemorrhage, or the association between clonal myeloproliferation and the progression to acute leukemia or myelofibrosis, controversy exists regarding the timing and nature of appropriate therapeutic intervention. Studies have shown that treatment with myelosuppressive agents such as chlorambucil, busulfan, radiophosphorus (32P), and hydroxyurea reduces the platelet count. However, investigators have also identified an increased risk of drug-related leukemic transformation. An ideal cytoreductive treatment for long-term use should minimize thrombosis and avoid long-term complications, especially acute leukemia (AL). Anagrelide, an imidazoquinolin, inhibits megakaryopoiesis and more selectively reduces platelet production in humans. A retrospective analysis of an open-label, multicenter, international trial reviewing 3660 anagrelide-treated patients was performed to assess efficacy and long-term safety, specifically potential for increased leukemogenicity. The study included MPD patients with thrombocytosis diagnosed according to Polycythemia Vera Study Group (PVSG) criteria. Of all patients enrolled, 81% had previously received other myelosuppressive agents; of these, 33% were transferred from the original agent to anagrelide due to toxicity and 31% were transferred because of poor platelet control. Over 45% of patients were symptomatic due to thrombocythemia, most commonly vascular sequelae (25%). Dosage was titrated to achieve a platelet count < 600 x 10(9) L(-1) and ideally between 130 and 450 x 10(9) L(-1). The safety cohort of 3660 patients, including 2251 with essential thrombocythemia (ET), 462 with polycythemia vera (PV), and 947 with chronic myeloid leukemia (CML) and other MPDs, was analyzed to establish the incidence of leukemic transformation in patients with ET and PV. From the Safety Population, 12.8% (467/3660) of patients were treated with anagrelide as the sole cytoreductive agent (naive patients). Acute leukemia/myelodysplasia developed in 2.1% of ET patients (47/2251) with a maximum follow-up of 7.1 years. Of the PV patients, 2.8% developed acute leukemia/myelodysplastic syndrome (13/462), with a maximum follow-up of 7.0 years. ET and PV patients who transformed to AL had all been previously exposed to other cytotoxics; there were no ET or PV patients in the study who transformed to AL exposed solely to anagrelide. With maximum follow-up over 7 years, anagrelide achieved platelet control in over 75% of MPD patients and did not increase the conversion to acute leukemia during the treatment duration analyzed. Longer follow-up is required to confirm these important observations regarding the long-term safety of anagrelide.
journal_name
Leuk Resjournal_title
Leukemia researchauthors
Fruchtman SM,Petitt RM,Gilbert HS,Fiddler G,Lyne A,Anagrelide Study Group.doi
10.1016/j.leukres.2004.10.002keywords:
subject
Has Abstractpub_date
2005-05-01 00:00:00pages
481-91issue
5eissn
0145-2126issn
1873-5835pii
S0145-2126(04)00373-Xjournal_volume
29pub_type
杂志文章,多中心研究abstract::Chronic B-lymphocytic leukemia (B-CLL) cells may be regulated by immune functions. In an attempt to analyze such functions, helper factors (IL-1 alpha, IL-1 beta and IL-6), T-cell products (sCD4 and sCD8) and sIL-2R and beta 2-microglobulin were measured in serum of patients at different stages of the disease. Patient...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/0145-2126(92)90009-v
更新日期:1992-06-01 00:00:00
abstract::Aberrant expression of tumor suppressor genes WT 1, RB 1, p53, homozygous deletion of p16 gene and their relationship with expression of oncogenes BCR-ABL, TEL-AML 1, MLL-AF 4, E2A-PBX 1, SIL-TAL 1 were determined in bone marrow samples of children with de novo B-lineage (n=170) and T-lineage (n=25) acute lymphoblasti...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/j.leukres.2005.04.006
更新日期:2005-11-01 00:00:00
abstract::Human peripheral blood monocytes were found to be capable of phagocytizing human B-non Hodgkin's lymphoma (NHL) cells coated with mouse monoclonal antibodies (MoAbs). The MoAbs used recognized idiotypic determinants on the surface immunoglobulin (Ig) of the tumor cells. MoAbs of IgG1 and IgG2a subclass were equally ef...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/0145-2126(86)90344-9
更新日期:1986-01-01 00:00:00
abstract::FcRIII (CD16) expression on neutrophils from 17 patients with chronic myeloid leukemia (CML) was studied by flow cytometry using monoclonal antibodies. A variable proportion of CD16-negative neutrophils were found both in CML patients in chronic phase (3 out of 8 patients) and in CML patients in hematological remissio...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/0145-2126(92)90120-v
更新日期:1992-12-01 00:00:00
abstract::We describe a 79-year-old man who had massive pleural effusion and a proliferation of prolymphocytic leukemia cells in the peripheral blood, bone marrow, and pleural effusion fluid. Immunophenotyping of leukemia cells revealed either CD3+CD4+CD8-CD25+ or CD3+CD4+CD8+CD25+. The antibody against human T-cell lymphotropi...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/j.leukres.2006.02.029
更新日期:2007-03-01 00:00:00
abstract::Leukotrienes and lipoxins are bioactive lipoxygenase products formed by leukocytes alone or in collaboration with other cells. While the physiological role of lipoxins remains to be clarified, accumulating evidence shows that leukotrienes are important mediators in asthma and inflammation. Consequently, recent clinica...
journal_title:Leukemia research
pub_type: 杂志文章,评审
doi:10.1016/0145-2126(94)90053-1
更新日期:1994-10-01 00:00:00
abstract::Stem cell factor (SCF) is a growth factor that promotes the survival, proliferation, and differentiation of hematopoietic cells. SCF and its receptor, Kit, are normally present in both cell surface and soluble forms. Both forms of Kit can bind SCF. However, the function of soluble Kit is unknown. In order to determine...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/s0145-2126(00)00122-3
更新日期:2001-05-01 00:00:00
abstract::We investigated Syk as a potential marker of CML progression. We observed a significant over-expression of Syk mRNA and constitutive phosphorylation of Syk Y348 in blast cells from six AP or BP-CML, but not in 15 CML in chronic phase. We could follow in vivo the recurrence of pSyk(348) throughout blast cell escape, de...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/j.leukres.2014.11.014
更新日期:2015-03-01 00:00:00
abstract:BACKGROUND:Most patients with myelodysplastic syndromes (MDS) require transfusions at the risk of iron overload and associated organ damage, and death. Emerging evidence indicates that iron chelation therapy (ICT) could reduce mortality and improve survival in transfusion-dependent MDS patients, especially those classi...
journal_title:Leukemia research
pub_type: 杂志文章,多中心研究
doi:10.1016/j.leukres.2014.02.003
更新日期:2014-05-01 00:00:00
abstract::As a part of our continuing efforts to develop gene therapy for acute myelogenous leukemia (AML), this study was undertaken to evaluate the possibility of using autologous bone marrow stromal fibroblasts (BMSFs) as a target cell population. Autologous BMSFs in AML were isolated from the stromal layers of long-term bon...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/s0145-2126(01)00134-5
更新日期:2002-04-01 00:00:00
abstract::Treatment of CMML remains a clinical challenge, with no drug demonstrating clear clinical benefit. Even if azacitidine is approved in the treatment of CMML, its role remains disputed. We report a cohort of 76 CMML patients (according to WHO classification) treated with azacitidine in 3 programs (French AZA compassiona...
journal_title:Leukemia research
pub_type: 临床试验,杂志文章
doi:10.1016/j.leukres.2013.01.004
更新日期:2013-06-01 00:00:00
abstract::Testis-specific gene antigen (TSGA10) is expressed in fetus, testis and frequently in human solid cancers and acute leukemias, making it a candidate for immunotherapy and for detection of minimal residual disease (MRD). This gene is considered as a member of cancer-testis (CT) genes. We previously demonstrated TSGA10 ...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/j.leukres.2005.11.012
更新日期:2006-07-01 00:00:00
abstract::We hypothesized that the high early death rate (EDR) due to bleeding in acute promyelocytic leukemia (APL) is in part attributable to delays in all- trans retinoic acid (ATRA). We conducted a retrospective analysis of the timing of ATRA administration. 204 consecutive patients with newly diagnosed APL between 1992 and...
journal_title:Leukemia research
pub_type: 杂志文章,多中心研究
doi:10.1016/j.leukres.2013.05.007
更新日期:2013-09-01 00:00:00
abstract::Dose reductions or interruptions may be required to manage treatment-associated adverse events among patients with myelodysplastic syndromes (MDS) treated with lenalidomide; such modifications are recommended to sustain therapy and maximize treatment duration. The aim of this retrospective case-control study was to de...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/j.leukres.2017.10.005
更新日期:2017-12-01 00:00:00
abstract::A prospective case-control study of the aetiologic factors involved in the production of lymphoid malignancies has been conducted within a defined geographical area covering six health districts in the Yorkshire Region. Among the aspects investigated were past medical events, occupations and certain social factors. A ...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/0145-2126(84)90016-x
更新日期:1984-01-01 00:00:00
abstract::Information about the expression of some myelomonocytic markers in lymphocytes of patients with B-CLL is scarce. We studied the CD13, CD14, CD11c and CD68 surface antigens in 42 controls and in 38 patients with B-CLL to detect their possible reactivity. Eighty-nine percent of B-CLL expressed very strongly the CD14 ant...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/0145-2126(92)90177-9
更新日期:1992-01-01 00:00:00
abstract::The presence of intracellular cytoplasmic immunoglobulin M (IgM) in leukemic cells from patients with acute lymphocytic leukemia (ALL) and chronic lymphocytic leukemia (CLL) was investigated by flow cytometry. The objective of the study was to develop a reproducible flow cytometric method. A Burkitt's lymphoma-derived...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/0145-2126(85)90126-2
更新日期:1985-01-01 00:00:00
abstract::In this case-control study, interview data on smoking habits were available for 179 de novo cases (116 with cytogenetic data) of acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). Smoking habits were compared with a pooled set of population controls and hospital controls (diagnosed with malignant melanom...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/j.leukres.2008.10.009
更新日期:2009-06-01 00:00:00
abstract::The myelodysplastic syndromes (MDS) are a diverse group of clonal hematopoietic malignancies characterized by ineffective hematopoiesis, progressive bone marrow (BM) failure, cytogenetic and molecular abnormalities, and variable risk of progression to acute myeloid leukemia (AML). The BM microenvironment in MDS plays ...
journal_title:Leukemia research
pub_type: 杂志文章,评审
doi:10.1016/j.leukres.2015.06.017
更新日期:2015-10-01 00:00:00
abstract::A bioassay was developed to assess P-glycoprotein (P-gp) function of peripheral blood natural killer (NK) cells and AML blasts during zosuquidar infusion. Cells were incubated with the fluorescent dye DiOC(2)(3) in the presence and absence of zosuquidar, and dye accumulation measured by flow cytometry. The assay perfo...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/j.leukres.2008.09.020
更新日期:2009-06-01 00:00:00
abstract::Based on Bcl-X(L) overexpression studies we identified type I and type II follicular lymphoma cell lines in response to TRAIL. We demonstrate here that either amount of caspase-8 activation or Bid cleavage could not define the dependence on mitochondria. Furthermore, an inhibitor of NF-kappaB, PDTC, enabled TRAIL to a...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/j.leukres.2008.09.025
更新日期:2009-06-01 00:00:00
abstract::A total of 854 patients with anti-HTLV-I antibody positive ATL, newly diagnosed from 1983 to 1987, were analyzed for prognostic factors. There were 466 males and 388 females with a mean age of 57.1. Of these 269 (31.5%) were alive with a median follow-up time of 14 months from diagnosis, while 585 (65.5%) were dead wi...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/0145-2126(91)90087-a
更新日期:1991-01-01 00:00:00
abstract::Smoking is associated with both acute myeloid leukemia (AML) and lung cancer. We therefore searched our database for concomitant presentation of AML and lung cancer. Among 775 AML cases and 5225 lung cancer cases presenting to Roswell Park Cancer Institute between the years January 1992 and May 2008 we found 12 (1.5% ...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/j.leukres.2008.12.016
更新日期:2009-09-01 00:00:00
abstract::Thermal stress induces expression of a family of heat shock proteins which may regulate the synthesis of various cellular genes. We investigated the effect of heat shock on polyadenylation in Epstein-Barr Virus (EBV) negative and EBV transformed human Burkitt's lymphoma (BL) B-cell lines. Incubation of the BL B-cell l...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/0145-2126(95)00063-1
更新日期:1995-11-01 00:00:00
abstract::Patients with FLT3-ITD mutated (FLT3-ITD+) Acute Myeloid Leukemia (AML), have frequently relapsed or refractory disease and FLT3-ITD+ inhibitors have limited efficacy. Rho kinases (ROCK) are constitutively activated by FLT3-ITD+ in AML via PI3 kinase and Rho GTPase. Upon activation by ROCK, LIM kinases (LIMK) inactiva...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/j.leukres.2020.106490
更新日期:2020-12-13 00:00:00
abstract::In order to establish diagnostic criteria for hypocellular acute leukemia (HL), we have reviewed 32 cases selected on the basis of hypothetical 40% or less cellularity, by focusing on morphology, immunophenotype, karyotype and response to low dose Ara-C (LDAC) regimen and compared them with 40 cases of myelodysplastic...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/0145-2126(95)00136-0
更新日期:1996-07-01 00:00:00
abstract::With the application of adequately sensitive tests, it is now becoming evident that more than 90% of patients with conventionally-defined polycythemia vera (PV) carry the somatic JAK2V617F mutation in their granulocytes. However, the specific mutation is also found in other classic and atypical myeloproliferative diso...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/j.leukres.2006.01.004
更新日期:2006-06-01 00:00:00
abstract::Myelodysplastic syndromes (MDS) are a group of clonally-acquired blood disorders characterized by ineffective hematopoiesis leading to cytopenias. Red blood cell transfusions are an important component of supportive care in patients with MDS. Prolonged exposure to transfusions can lead to iron overload, which results ...
journal_title:Leukemia research
pub_type: 杂志文章,评审
doi:10.1016/j.leukres.2017.10.001
更新日期:2017-11-01 00:00:00
abstract::The chemicals 6-mercaptopurine (6-MP) and methotrexate (MTX) are the cornerstones in the maintenance treatment of acute lymphoblastic leukemia. The intracellular metabolism of 6-MP to 6-thioguanosine nucleotides (TGN) via 6-thioinosine 5'-monophosphate (TIMP) is crucial for its cytotoxic effect. MTX inhibits purine de...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/0145-2126(92)90065-f
更新日期:1992-01-01 00:00:00
abstract::Predisposition to lymphomagenesis is a well-known phenomenon of ataxia-telangiectasia, a recessive disorder caused by germline inactivation of ATM. ATM encodes a protein implicated in the repair of radiation induced double-strand breaks. Biallelic ATM inactivation was described also in sporadic lymphoid malignancies, ...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/j.leukres.2005.11.010
更新日期:2006-09-01 00:00:00